Business
FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial
KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced that it has submitted an Investigational ...
About this update from Fluoguide A/s
[{"type":"text","content":"KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for FG001. The IND supports the initiation of the Company's first registration trial in patients with high-grade glioma (HGG).","length":472,"tagName":"p"},{"type":"text","content":"The IND submission represents a key regulatory milestone for FluoGuide and marks the transition of FG001 to late-clinical development, advancing the program toward U.S. registration. Initiation of the first registration trial remains on track, with enrollment of the first patient expected in Q2 2026.","length":301,"tagName":"p"},{"type":"text","content":"IND submission - foundation for U.S. registration","length":49,"tagName":"p"},{"type":"text","content":"An Investigational New Drug (IND) application is required to obtain U.S. regulatory authorization to initiate clinical trials of a new drug. FG001 is a well-advanced, clinical-stage product, and significant portions of the submitted IND package, including the preclinical section, are expected to form the basis of the future New Drug Application (NDA) required to obtain approval to market FG001 in the U.S.","length":408,"tagName":"p"},{"type":"text","content":"Prior to submission, FluoGuide held a pre-IND meeting with FDA, during which the agency reviewed a comprehensive development package covering completed work and proposed plans for ongoing studies.","length":196,"tagName":"p"},{"type":"text","content":"Importantly, FluoGuide received FDA alignment on the design of its U.S. Phase 2 clinical trial in HGG to support registration, as well as on key elements of the subsequent Phase 3 program.","length":188,"tagName":"p"},{"type":"text","content":"This regulatory alignment provides a strong foundation for the long-term development planning, and in our view, de-risks the regulatory process as we advance toward NDA submission and future U.S. approval of FG001.","length":214,"tagName":"p"},{"type":"text","content":"First registration trial - clear regulatory path","length":48,"tagName":"p"},{"type":"text","content":"FluoGuide anticipates that two clinical trials w...